| # | Drug | Count |
|---|---|---|
| 0 | CAPECITABINE | 24 |
| 1 | EVEROLIMUS | 24 |
| 2 | FULVESTRANT | 24 |
| 3 | RANITIDINE | 24 |
| 4 | FENTANYL | 23 |
| 5 | MEFENAMIC ACID | 22 |
| 6 | PAMIDRONATE DISODIUM | 20 |
| 7 | VEDOLIZUMAB | 16 |
| 8 | NATALIZUMAB | 10 |
| 9 | PALBOCICLIB | 10 |
| # | Drug | Count | Frequency |
|---|---|---|---|
| 0 | MEFENAMIC ACID | 22 | 0.0099 |
| 1 | PAMIDRONATE DISODIUM | 20 | 0.0059 |
| 2 | CROTALIDAE IMMUNE F(AB)2(EQUINE) | 1 | 0.0053 |
| 3 | GADOPICLENOL | 1 | 0.0036 |
| 4 | TALIGLUCERASE ALFA | 1 | 0.0017 |
| 5 | INFLIXIMAB-DYYB | 4 | 0.0012 |
| 6 | FULVESTRANT | 24 | 0.0007 |
| 7 | APOMORPHINE HYDROCHLORIDE | 1 | 0.0006 |
| 8 | ALPHA1-PROTEINASE INHIBITOR (HUMAN) | 1 | 0.0005 |
| 9 | EVEROLIMUS | 24 | 0.0005 |
| # | Drug class | Count |
|---|---|---|
| 0 | Nonsteroidal Anti-inflammatory Drug [EPC] | 33 |
| 1 | Estrogen Receptor Antagonist [EPC] | 24 |
| 2 | Kinase Inhibitor [EPC] | 24 |
| 3 | Nucleoside Metabolic Inhibitor [EPC] | 24 |
| 4 | mTOR Inhibitor Immunosuppressant [EPC] | 24 |
| 5 | Opioid Agonist [EPC] | 23 |
| 6 | Corticosteroid [EPC] | 16 |
| 7 | Integrin Receptor Antagonist [EPC] | 16 |
| 8 | Osmotic Laxative [EPC] | 6 |
| 9 | Expectorant [EPC] | 5 |
| # | Drug class | Count | Frequency |
|---|---|---|---|
| 0 | Estrogen Receptor Antagonist [EPC] | 24 | 0.0006 |
| 1 | Calcitonin Gene-related Peptide Antagonist [EPC] | 3 | 0.0003 |
| 2 | Hydrolytic Lysosomal Glycogen-specific Enzyme [EPC] | 1 | 0.0003 |
| 3 | Hydrolytic Lysosomal Neutral Glycosphingolipid-specific Enzyme [EPC] | 2 | 0.0002 |
| 4 | Anticholinergic [EPC] | 3 | 0.0002 |
| 5 | Integrin Receptor Antagonist [EPC] | 16 | 0.0002 |
| 6 | Hydrolytic Lysosomal Glucocerebroside-specific Enzyme [EPC] | 1 | 0.0001 |
| 7 | Human Immunoglobulin G [EPC] | 2 | 0.0001 |
| 8 | Nucleoside Metabolic Inhibitor [EPC] | 24 | 0.0001 |
| 9 | Opioid Agonist [EPC] | 23 | 0.0001 |